-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27

Benzinga·07/08/2026 10:09:18
Listen to the news
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.